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We previously  demonstrated  the  occurrence of a 
naturally  arisen  human  anti-idiotypic B cell  clone, 
that we  transformed  with EBV (EBV383). We show 
evidence  that  EBV383  not  only expresses  the CD5 
surface Ag, but also contains  the  2.7-kb mRNA tran- 
script  encoding this protein. In addition, we show 
the  presence of the  3.6-kb mRNA precursor.  Most Ig 
produced  by CD5+ B cells are  polyreactive  natural 
IgM antibodies encoded by unmutated copies of 
germline VH genes. However,  in this study we  pres- 
ent  data  demonstrating  the  monoreactive  high  affin- 
ity  character of the  anti-idiotypic  antibody 
(mAb383)  produced  by  EBV383.  These  data  are  in 
agreement  with our previous  observations,  showing 
that  the VH chain of  mAb383 is encoded by an  ex- 
tensive  somatically  mutated VHV gene  in a way that 
is consistent with  an  Ag-driven  immune  response. 
A possible role for this remarkable anti-idiotypic 
antibody in the maintenance of B cell memory is 
discussed. 
Analysis of the B cell compartment of mouse  and  man 
has revealed  evidence for  the  existence of B cell subpop- 
ulations/lineages  with  different  phenotypical  and  func- 
tional  characteristics  (1 -6). First a population of conven- 
tional CD5- B cells (Ly-1 in the mouse and Leu 1 in 
humans)  exists  that undergoes clonal expansion in re- 
sponse  to  T-dependent Ag and  establishes acquired hu- 
moral  immunity  and immunological  memory  (7-1 1). Ac- 
tivation of memory B cells upon re-encounter with Ag 
results  in  the  production of specific  antibody  with  high 
affinity  for  the Ag. Somatic  hypermutation  acting  selec- 
tively on rearranged antibody V region genes and Ag- 
driven  selection of mutations  are  at  the  basis of affinity 
maturation of this specific  antibody  response  (7-10). A s  
opposed  to these  conventional CD5- B  cells, CD5' (IgM+ 
> IgD') B cells  apparently do not  participate  in  conven- 
tional  immune  response  but  instead  produce low affinity 
Received  for publication May 15. 1990. 
Accepted  for publication December 5,  1990. 
payment of  page charges. This article must therefore be  hereby  marked 
The costs of publication of this article were defrayed in part by the 
advertisement in accordance with 18 U.S.C. Section 1734 solely to indi- 
cate this  fact. 
nologie, The  Hague,  The Netherlands [PCB 63107). 
This work was supported by a grant from  Programmabureau Biotech- 
' Address correspondence and reprint requests to Dr. R. W. J. van der 
tion. Laboratory of Immunobiology. P.O. Box I ,  3720 BA Bilthoven. The 
Heijden. National Institute of Public Health and Environmental Protec- 
Netherlands. 
tional BV. 5340 BH Oss, The Netherlands. 
Present address Scientific Development Group, Organon Interna- 
multireactive IgM antibodies  with  self-reactivity  and  with 
reactivity  towards a variety of microbial Ag (1, 1  1-22). 
For the reactivity of their IgM antibodies,  their  strategic 
anatomical distribution in peripheral lymphoid tissues 
and  their relative  predominance  in  early  ontogeny,  it is 
likely that CD5+ B  cells  make a n  important  contribution 
to the  establishment of "natural  immunity"  (1, 9, 1  1-25). 
So far available data on the expression of V genes by 
CD5+ B  cells in  the  mouse  and  humans suggested,  con- 
current with  their proposed function,  preferential  usage 
of VH and VL germline  genes  in  the  absence of somatic 
mutation  (26-31). 
Our  previous work  described the molecular  character- 
ization of a human monoclonal  anti-idiotypic 1gM anti- 
body produced by a n  EBV-transformed  B cell clone 
(EBV383) expressing CD5 as demonstrated by cytofluo- 
rometric  analysis  (32).  The VH chain of this antibody  was 
derived from the VHV family of human V region gene 
segments. Parallel studies on the germline VHV gene 
isolated from the same adult, healthy donor revealed 
extensive  somatic  mutation  in  the  expressed VHV gene 
leading  to  amino  acid  replacements  accumulating  in CDR 
I, CDR 11, and  framework I11 (33). 
In the  present  report we extend  our  previous  studies 
suggesting a n  Ag-driven immune response by CD5+ B 
cells. In addition  to  surface  expression of CD5, we show 
that  the EBV-transformed  B cell clone  EBV383 contains 
the  2.7-kb mRNA transcript coding for  the CD5 protein 
as well as the  3.6-kb mRNA precursor. In agreement  with 
the previously  observed  extensive somatic  variability of 
its V region, we find that  the IgM antibody  secreted by 
EBV383 shows a monospecific and high  affinity  binding 
(Kd = 8.67 X lo-' mol/liter)  to its putative  ligand, i.e., the 
These  studies,  together  with  our  previous work have 
consequences  for  our  understanding of repertoire  selec- 
tion  in at least  the  human CD5 B cell compartment. We 
discuss  the possibility that somatically  mutated  antibody 
V regions of anti-idiotypic CD5+ B  cells  function as "per- 
sistent Ag" to  maintain  the  function f long-lived conven- 
tional  memory  B  cells in  the  absence of Ag. 
Id 6- 15C4. 
MATERIALS AND METHODS 
Virus  strains and peptides. The Pitman-Moore strain of rabies 
virus  was propagated in dog kidney  cells.  Rabies  virus Ag (dog kidney 
cell vaccine) was prepared as described previously (34). Synthetic 
peptides  corresponding to certain  parts of the  rabies  virus glycopro- 
tein (35,36) were  obtained  from  the  European  Veterinary Laboratory 
[Amsterdam,  The  Netherlands). 
Rabies  virus neutralizing mAb (rnAbG-l5C4). The  establishment 
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and characterization of mAb6-15C4 has been described in detail 
previously (37). For the  experiments described  in this  study, mAb6- 
Sepharose affinity chromatography (Pharmacia Fine  Chemicals, 
15C4 was Isolated from tissue culture supernatant by protein A- 
Uppsala, Sweden). Subclass  determination (IgG2b). the L chain com- 
position (K). virus neutralizing  activity, and  its delineation of a se- 
quential  determinant on the  rabies  virus glycoprotein have  also been 
reported elsewhere (37). 
donor was vaccinated intramuscularly with one dose of dog kidney 
EBV transformation and  cloning of cells. A healthy  adult  human 
cell vaccine. This procedure was repeated  on days 7 and 2 1. After 2 
yr the donor was revaccinated and 2 yr after  the  last vaccination, 
PBMC were isolated, EBV transformed. and cloned as  described 
before (32). 
ELISA. Microtiter plates  (Titertek type 111, Flow Laboratories, Ir- 
carbonate  buffer pH 9.6. All other  incubations were  carried  out in 
vine, Scotland] were coated overnight with antibodies in 0.1 M 
0.05% Tween 80,  and 1 M NaC1. Incubations with antibodies or Ag 
PBS containing 1% BSA (Organon Teknika, Oss. The  Netherlands], 
were  carried out  at 37°C for  1 h. To determine antibody reactivity 
against mAb6- 15C4,  microtiter plates were coated with mAb6- 15C4 
or with a panel of control murine monoclonal antibodies of the  same 
isotype (IgC2b.r). a t  a concentration of 3 pg/ml. Culture  supernatant 
of EBV383 was  titrated  on  the  test plate or control plate  and  the 
bound antibody was detected with horseradish peroxidase-conju- 
gated rabbit  anti-human IgM Ig (Dakopatts.  Glostrup. Denmark). All 
plates were developed for 10 min at  room temperature  using  100 rl/ 
was stopped with 1 M H2S04 and  at  450  nm  absorbance  was read 
well of tetramethylbenzidine substrate solution (38).  This reaction 
by a Titertek  Multiscan (Flow Laboratories, McLean, VA). Results of 
triplicate samples were  expressed as mean  absorbance value. 
Inhibition ELISA was carried out as follows. After overnight in- 
cubation a t  room temperature of 10 ng of mAb383 with 0, 0.15,  1.5, 
15,  and  150 pg. respectively. of mAb6-15C4. rabies  virus Ag, peptide 
G5, an irrelevant  control  peptide E l  25,  and  several  irrelevant control 
murine mAbs with the  same isotype as mAb6-15C4. these  incuba- 
tion mixtures were placed on  microtiter plates coated with mAb6- 
15C4 as described  above. mAb383 activity  in these  incubation mix- 
tures  was detected with horseradish peroxidase-conjugated rabbit 
anti-human IgM lg (Dakopatts).  The inhibition ELlSA was developed 
and  absorbance  was  measured as described above. Results of trip- 
licate samples were expressed a s  mean percentage  inhibition  value 
according to the formula: 
percentage  inhibition 
- (OD450 nm  uninhibited - OD450 nm  test) 
OD450 nm uninhibited 
x 100. 
To detect  a possible multireactivity of mAb383. the antibody was 
analyzed  in  a  direct  binding ELISA for  reactivity with dsDNA. ssDNA. 
and cytochrome C. The direct  binding ELISA was  carried out  exactly 
thyroglobulin,  cardiolipin, insulin, TNP, DNP. human IgG Fc, OVA, 
with the Ag mentioned above. These plates were incubated with 
as reported elsewhere (39). Briefly, microtiter plates were coated 
supernatants  containing  mAb383  and  the positive controls.  respec- 
tively. Binding of any of these  antibodies to any coat was detected 
with alkaline phosphatase-conjugated goat anti-human IgM. The 
ELISA was developed with substrate (2.3 mM p-nitrophenylphos- 
phate in 1 M diethanolamine, 0.25 mM  MgClz, pH 9.8) and the 
reaction was stopped by adding  2.4 N NaOH. Absorbance was read 
at  405  nm by a Titertek multiscan  (39). 
FMF.4 FMF was performed on EBV383 and a CD5- EBV-trans- 
formed human B ceil, EBV655. that produced an IgM,K antibody (40). 
EBV-transformed B  cells were incubated  in 0.1 m1 of ice cold  PBS. 
containing 1% BSA with: FITC-labeled mouse lgG2a anti-human 
CD5  mAb (anti-Leu 1. Becton Dickinson Immunocytometry Systems. 
Mountain View,  CA); phycoerythrin-labeled  mouse IgCl anti-human 
CD19  mAb (anti-Leu 12. Becton Dickinson); FITC-labeled goat F(ab’)* 
F(ab’), anti-human K-chain (Tago Inc.).  Phycoerythrin-labeled  mouse 
anti-human A-chain (Tago Inc..  Burlingame. CA): FITC-labeled goat 
labeled mouse IgG2a anti-human CD2 mAb (anti-Leu 5B. Becton 
IgGl anti-human CD3 mAb (anti-Leu 4, Becton Dickinson) and FITC- 
Leu 1. respectively. Cells were analyzed with a FMF scan (Becton 
Dickinson)  were  used a s  isotype controls  for anti-Leu  12  and  anti- 
Dickinson) and  results of double labeling experiments  are depicted 
as contourgraphs. 
Northern blotting and probes. Total RNA was  extracted  from lo7 
EBV transformed B  cells or lo’ human T cells a s  described previ- 
ously (41). Total RNA was  separated on 1% agarose gel, blotting to 
Genescreen  Plus membranes (NEN Research  Products, Boston, MA) 
Abbreviations  used  in this paper: FMF, flow mlcrofluorimetry:  Ars. 
hapen p-azophenyl arsonate. 
and hybridization was done  according to the  manufacturers speci- 
fications.  Membranes were washed under high stringency conditions 
(2X SSC. 65°C for 30 min (twice),  0.1 x SCC, room temperature for 
Dr. N. Jones.  Dana-Farber  Institute. Boston, MA) was 32P-labeled by 
30 min).  Human CD5 specific cDNA probe (42) (kindly provided by 
random hexamer  priming as described previously (43). Membranes 
were exposed on Kodak XAR film (Eastman Kodak. Rochester, NY) 
by using amplifying screens. 
Inhibition studles of human mAb383 binding to so(Ld phase 
K d .  Aliquots of  PBS (0.05 ml) containing  0.05% Tween 20  and 0.1% 
murine mAb6-15C4 by sotubte mAb6-15C4 and  calcutation of the 
BSA (PBS-Tween-BSA) and 1 X 10”’ mol/liter mAb383 were mixed 
with  aliquots of PBS-Tween-BSA with increasing  amounts of soluble 
mAb6-l5C4  (6.7 X lo-’’ to 1 X lo-’ mol/liter). After an  18-h  incu- 
bation at  room temperature, the mixtures were transferred into 
ELISA plates coated with 3 pg/ml mAb6-l5C4 as described above. 
After 1-h  incubation and  subsequent  washing with PBS-Tween, the 
amount of mAb383  bound to the solid phase mAb6-15C4 was de- 
tected with HRPO-conjugated rabbit  anti-human IgM Ig as  described 
above. mAb383  binding  in the  presence of soluble ligand was ex- 
pressed as percentage of its binding  activity  measured under iden- 
tical  conditions but in complete absence of any soluble ligand. The 
mAb Kd values were  calculated  according to Friguet et  al.  (44). 
RESULTS 
Clone EBV383 is CD5+ B cell. The  phenotype of clone 
EBV383 was  determined by dual color flow cytometric 
analysis. Cells were stained with pE-labeled anti-CD5 
mAb and with FITC-labeled goat  F(ab’), anti-human X or 
K L chain-specific antibody. Staining profiles are illus- 
trated  in Figure  1. Clone EBV655,  derived  from the same 
cloning event, was used as a control. Although both 
clones  show  expression of CD19. clone  EBV383 bears X 
L chain  and  expresses CD5, whereas clone EBV655 bears 
K L chain  and  appears to be CD5-. Repeated  analysis at 
several  occasions  during a period of 15 mo of culture of 
EBV383 shows  identical  results  indicating a stable 
expression of CD5 on EBV383. 
To demonstrate  the mRNA transcript  for  the CD5 mol- 
ecule,  Northern blot analysis  was performed on total RNA 
isolated  from EBV383,  EBV655, and  human T  cells. The 
cDNA probe  used,  was  obtained  from  the  human CD5/ 
Tl/Leu 1 cDNA clone  pT1-2 (42). Both the  3.6-kb mRNA 
precursor  and  the  2.7-kb mRNA transcript  are detected 
in  total RNA isolated  from  EBV383 (Fig. 2, lanes 1 and 
2) and from human T  cells (lanes 5 and 6). CD5 surface 
Ag encoding mRNA is  lacking  in EBV655. A small RNA 
fragment  with  unknown specificity is also visible in Fig. 
2, lanes 1 and 2 and 5 and 6. Taken together these 
results  characterize EBV383 as a CD5’ B cell clone. 
EBV383 secretes a high affinity monoreactive  anti- 
idiotypic  antibody (mAb383). Non-T cells of a healthy 
adult  individual,  who  had  been  deliberately  immunized 
with  rabies  vaccine,  were  transformed  with EBV. Clone 
EBV383 was selected after EBV transformation  and lim- 
iting  dilution twice on basis of the anti-idiotypic  reactivity 
of its culture  supernatant  with  the  murine Id 6-15C4. 
mAb6-15C4 is a rabies  virus  neutralizing  antibody di- 
rected against a linear  epitope  on  the  rabies  virus glyco- 
protein (37). Inasmuch as it has  been  demonstrated  that 
the pool of natural IgM antibodies produced by CD5+ B 
cells  contains a high  proportion of multireactive  specific- 
ities including self-specificities, experiments were per- 
formed to substantiate the anti-idiotypic specificity of 
mAb383. 
Culture supernatants of EBV383  were tested  for  bind- 
ing to exogeneous Ag, haptens, autoantigens, Id other 
than  6-15C4  rheumatoid  factor  activity.  Culture  super- 
natants of EBV-transformed B cells from neonatal or 
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Figure I .  FMF of EBV383 (upper row) and EBV655 (lower row). lsotype control. fluorescence 1 (FLI):  mouse lgG2a anti-human CD2 FITC: 
FLI: goat F(ab'),  anti-human X FITC:  FL2: mouse lgCl anti-human CD19 PE. Anti-CD5. FLI:  mouse IgC2a anti-human CD5  FITC:  FL2: mouse lgCl 
anti-human CD19 PE. 
1 2  3 4  5 6  
> 
> 
probe (as described in Materials and Methods). Lanes I and 2. 7.5  and 
Figure2. Autoradiogram of Northern blot probed with a CD5-specific 
7.5  and  15 pg respectively of total RNA isolated from EBV655 (an irrele- 
15 pg. respectively. of total RNA isolated from ERV383: lanes 3 and 4.  
vant  human IgM producing CD5- EHV-transformed B cell]: lanes 5 and 
6. 7.5 and 1 5  pg. respectively of total RNA isolated from a  human  T cell 
clone as  a positive control. Upper and lower arrows show the 3.6-kb 
precursor and  the  2.7-kb mRNA transcript  respectively. Also visible in 
lanes 1 and 2 and 5 and 6 is a lower unknown mRNA band. 
adult origin containing IgM antibody  with  known  activi- 
ties for one or more of the Ag or idiotypes were used as 
controls. The  results  summarized in Figure 3 show  that 
mAb383 is devoid of multireactive specificity and it 
shows only binding to the Id 6- 15C4. This monoreactivity 
of mAb383 was  further confirmed by the  results of in- 
hibition ELlSA experiments in which the binding of 
mAb383 to the idiotope of 6-15C4 was  measured in the 
IgC2b.w Id other  than mAb6-15C4  and  human IgFc to human IgM anti- 
Flgure 3. Hintling of exogrneous Ag. haptens. autoantigens. murine 
bodies produced by  EBV transformed  B cell lines of neonatal (w or  adult 
(A ]  origin. by EBV2022 (producing  a  human IgM antibody with an ex- 
pressed VHV gene. kindly provided by Dr. J. Thomas)  and by EBV383. 
Binding is presented by the shaded areas. 
presence of various  ligands and  antibodies as inhibitors. 
In Figure 4 it is demonstrated  that  the binding of mAb383 
to plate-bound mAb6- 15C4 is inhibited  in a dose-depend- 
ent fashion by either rabies virus or a 21 amino acid 
peptide G 5  representing  the epitope of the viral glycopro- 
tein that is recognized by mAb6-l5C4. but not by an 
irrelevant  21  amino acid peptide El  25 (32).  Furthermore, 
the binding of mAb383 to Id 6- 15C4 could only be inhib- 
ited by mAb6-l5C4,  but  not by other mAb of the IgG2b, 
K isotype. Based on  the  latter  results  the Kd of mAb383 
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Figure 4. Inhibition ELISA to demonstrate the recognition  of the idi- 
otype 6-15C4 by EBV383. Binding of mAb383 to mAb6-15C4-coated 
microtiter plates is inhibited by  peptide G5 (0). rabies virus Ag (O), murine 
IgG2b. I( mAb  from different origin [+j, an irrelevant  peptide E125 (e) and 
the homologous inhibitor mAb6-l5C4 (0). Percentage inhibition was cal- 
culated as described in Materials  and  Methods. 
for the Id 6- 15C4 was  calculated and revealed a value of 
8.67 X lo-' mol/liter. Thus, collectively, these  data sug- 
gest that mAb383 is a monoreactive antibody that binds 
with high affinity to an  idiotypic determinant located 
within or near  the Ag-binding site of mAb6- 15C4. 
DISCUSSION 
Human CD5' B lymphocytes belong to a subpopulation 
of cells that is endowed with the production of so-called 
natural antibodies  (1 -6). Multireactivity, self-reactivity, 
a low affinity  binding to Ag, and a biased use of unmu- 
tated copies of germline VH genes  are distinctive features 
of these, mostly IgM antibodies (1, 9, 11-31). 
In the light of these  data,  the combination of the  phen- 
otypical, functional, and molecular characteristics of 
clone EBV383 is remarkable. Our data clearly show that 
EBV383 is a CD5' B cell (Figs. 1 and 2). The possibility 
that CD5 expression may have been induced by our EBV 
transformation protocol is highly unlikely as EBV383 is 
the only B cell clone out of fifty clones  characterized by 
FMF analysis that shows expression of CD5. Further- 
more, most human CD5* chronic lymphocytic leukemia 
analyzed thusfar  are EBV-.  In addition to the phenotyp- 
ical characterization we showed that clone EBV383 pro- 
duces an IgM antibody that specifically reacts  with  the Id 
of mAb6-l5C4 only and  fails to react with any of the 
foreign Ag. haptens, or auto-Ag tested (Figs. 3 and 4). 
Thus, unlike most human CD5+ B lymphocytes, clone 
EBV383 produces a monoreactive IgM antibody which 
binds  with  high  affinity (Kd = 8.67 X lo-' mol/liter) to its 
putative  ligand, Le., the Id 6-15C4. This  finding is con- 
sistent  with  our previous observation  showing that  the 
VHV gene  xpressed by  EBV383 displays  extensive 
changes from the germline sequence leading to  amino 
acid replacements  accumulating  in CDR I, CDR 11, and 
framework 111 (33). 
Though the relative contribution of the antibody H and 
L chains of mAb383 in the high affinity  binding to the Id 
6-15C4 remains to be established,  our  findings suggest 
that EBV383 results from an affinity  maturation  process 
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brought about by the concerted action of somatic  muta- 
tion and Id affinity-based selection. This would  imply the 
use of an Id similar to the  murine 6- 15C4 Id in  the  human 
immune  response  against  rabies  virus, which possibility 
is being investigated. Alternatively, but  less likely given 
the Kd of mAb383, EBV383  may have been selected by 
an epitope of an as yet unknown foreign Ag that is 
strongly  cross-reactive  with the 6-15C4 Id.  For the  first 
time,  our  present and previous results show that normal 
human CD5+ B cells not unlike  conventional B cells may 
mature  to B cells expressing monospecific high affinity 
and somatically mutated antibody V regions. Our data 
are reminiscent of the  data by Harindranath  et aL5 who 
showed that high affinity IgM rheumatoid factors pro- 
duced by EBV-transformed CD5' human B cells display 
a  number of somatic  mutations in a way consistent  with 
an Ag-driven immune  response. Thus, in contrast to the 
situation  in  the  mouse, IgM-secreting CD5' B cells in man 
undergo somatic  hypermutation and affinity  maturation 
as conventional B cells do in response to Ag. However, it 
should be noted that in the mouse the possibility that V 
genes of Ly-1' B cells can be subject to  somatic hyper- 
mutation  in an  immune  response to T cell-dependent Ag 
by deliberate immunization, has not been directly ad- 
dressed.  Experiments of Naparstek  et al. (45) showed that 
the  unmutated VH segment used by CRI-A' antibodies of 
A/ J  mice in response  to the Ars also encoded IgM anti- 
bodies with multireactivity for ssDNA and cytoskeletal 
fibers. After immunization  with Ars, CRI-A+ antibodies 
expressing  somatic  mutations in VH showed high affinity 
binding  to Ars but lost their reactivity to autoantigens. 
However, thusfar, direct evidence for the production of 
CRI-A+ somatically mutated  anti-Ars  antibodies by Lyl' 
B cells in A/J mice remains  to be demonstrated. 
With regard to a physiologic  role of CD5+ B cells dis- 
playing characteristics  similar to EBV383, we envisage 
the following possibility. The  finding that  the high affin- 
ity binding of mAb383 to Id 6-15C4 can be completely 
inhibited by rabies  virus Ag or peptide G5, that represents 
an epitope of the viral glycoprotein, suggests that  the 
antibody V region of mAb383 may structurally resemble 
this G5  epitope (Fig. 4). Determination of the contribution 
of H and L chains of mAb383  in the binding to mAb6- 
15C4, elucidation of the nucleotide sequence of the VL of 
mAb383 and immunization  studies  with mAb383 as  sur- 
rogate Ag are required to test  this  assumption. If indeed 
mAb383 would appear to bear an image of the G5  epitope, 
the  interesting possibility arises  that upon immunization 
with Ag (Le., rabies virus vaccine), an Ag-specific Id- 
bearing B cell clone (Le., 6-15C4-like) due  to  its  increased 
frequency  signals and selects a somatically mutated anti- 
idiotypic B cell clone (i.e., EBV383). Such an anti-idi- 
otypic clone, because its somatically mutated antibody V 
region  now mimics the epitope (i.e.,  G5), may be depend- 
ent on the threshold of the antibodies that it produces, 
either allow the co-existence of idiotypic  long-lived mem- 
ory B cells specific for the mimicked epitope or signal and 
select  other idiotypic B cells with specificity for the epi- 
tope to develop to memory B cells. In both cases  B cell 
N. Harindranath, I. S. Goldfarb, H. Ikematsu, S. E. Burastero, R. L. 
Wilder, A. L. Notkins. and P. Casali. Complete sequence of the genes 
encoding the Vn and VL regions of  low and high affinity monoclonal IgM 
and IgA rheumatoid factors produced  by  CD5+ B cells from a rheumatoid 
arthritis patient. Submitted for publication. 
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memory will be  maintained in the  absence of Ag. If one 
considers  the  evidence  showing  that Id can be  processed 
and presented  in the form of idiopeptides in association 
with MHC class I1 molecules, the  presence of Ag-specific 
Th cells would be  sufficient  to  activate  both Ag-specific 
idiotypic and anti-idiotypic  B  cells  (46-50). 
The idea that B cell memory  may be subject  to idiotypic 
control has been  proposed earlier by others (5 1-53). How- 
ever,  our  version of this  general idea contains  some key 
elements, i.e.,  images of Ag carried  by  somatically  mu- 
tated V regions of anti-idiotypic antibodies of CD5+ B 
cells that would support  the views that immunological 
memory is a systemic rather  than a clonal  property (52, 
54).6 
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